Advances in research of gallbladder cancer organoid_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

YE Baolong ^1,2 , DING Kai ² ,  JI Wu ^1,2

1. The First College of Clinical Medicine, Southern Medical University, Guangzhou 510515, P. R. China;
2. Department of General Surgery, General Hospital of Eastern Theater Command, Nanjing 210002, P. R. China;

Corresponding author：

JI Wu, Email: jiwuvip@hotmail.com

Keywords：

gallbladder cancer; organoid; model; individualized treatment

DOI：

10.7507/1007-9424.202206023

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To summarize the progress and challenges in the research of gallbladder cancer organoid, and explore the possible solution strategies. Method The literature relevant to the researches of gallbladder cancer organoid at home and abroad in recent years was reviewed. Results The research of gallbladder cancer organoid was in its infancy. The gallbladder cancer organoid was mainly constructed from surgically resected gallbladder cancer tissues. Now the research of gallbladder cancer organoid had made some progress, such as on the pathogenesis and drug screening of gallbladder cancer. Conclusions The study on gallbladder cancer organoid can further understand the gallbladder cancer and help to speed up the update of diagnosis and treatment plan. However, the model of gallbladder cancer organoid is facing the challenges such as low construction success rate. The experience gained from organoids research in other diseases is worthy of reference.

Citation： YE Baolong, DING Kai, JI Wu. Advances in research of gallbladder cancer organoid. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2022, 29(12): 1648-1652. doi: 10.7507/1007-9424.202206023 Copy

1.	Tansey W, Li K, Zhang H, et al. Dose-response modeling in high-throughput cancer drug screenings: an end-to-end approach. Biostatistics, 2022, 23(2): 643-665.
2.	Wang H, Brown PC, Chow ECY, et al. 3D cell culture models: drug pharmacokinetics, safety assessment, and regulatory consideration. Clin Transl Sci, 2021, 14(5): 1659-1680.
3.	Di-Luoffo M, Pirenne S, Saandi T, et al. A mouse model of cholangiocarcinoma uncovers a role for tensin-4 in tumor progression. Hepatology, 2021, 74(3): 1445-1460.
4.	Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science, 2014, 345(6194): 1247125. doi: 10.1126/science.1247125.
5.	Bruun J, Kryeziu K, Eide PW, et al. Patient-derived organoids from multiple colorectal cancer liver metastases reveal moderate intra-patient pharmacotranscriptomic heterogeneity. Clin Cancer Res, 2020, 26(15): 4107-4119.
6.	Nanki Y, Chiyoda T, Hirasawa A, et al. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing. Sci Rep, 2020, 10(1): 12581. doi: 10.1038/s41598-020-69488-9.
7.	尹健一, 李幼生, 黎介寿. 小肠类器官的构建与应用进展. 中华实验外科杂志, 2019, 36(7): 1344-1347.
8.	范圣先, 尹健一, 王剑, 等. 胃干细胞调控机制及其在胃类器官构建中的应用研究. 中华消化外科杂志, 2019, 18(3): 287-291.
9.	李向阳, 赵鑫, 相小松, 等. 诱导型多能干细胞在体外三维环境中诱导分化出肠道类器官. 中国组织工程研究, 2017, 21(25): 4057-4061.
10.	耿艳霞, 黎介寿, 李秋荣. 肠道干细胞与肠道损伤修复的研究进展. 医学研究生学报, 2013, 26(2): 181-185.
11.	Huang Z, Ruan HB, Zhang ZD, et al. Mutation in the first Ig-like domain of Kit leads to JAK2 activation and myeloproliferation in mice. Am J Pathol, 2014, 184(1): 122-132.
12.	Yuan B, Zhao X, Wang X, et al. Patient-derived organoids for personalized gallbladder cancer modelling and drug screening. Clin Transl Med, 2022, 12(1): e678. doi: 10.1002/ctm2.678.
13.	Wang Z, Guo Y, Jin Y, et al. Establishment and drug screening of patient-derived extrahepatic biliary tract carcinoma organoids. Cancer Cell Int, 2021, 21(1): 519. doi: 10.1186/s12935-021-02219-w.
14.	袁波. 胆囊良恶性肿瘤类器官培养体系的建立及鉴定. 上海: 中国人民解放军海军军医大学, 2019.
15.	Kasuga A, Semba T, Sato R, et al. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice. Cancer Sci, 2021, 112(5): 1822-1838.
16.	Pérez-Moreno P, Riquelme I, García P, et al. Environmental and lifestyle risk factors in the carcinogenesis of gallbladder cancer. J Pers Med, 2022, 12(2): 234. doi: 10.3390/jpm12020234.
17.	Erlangga Z, Wolff K, Poth T, et al. Potent antitumor activity of liposomal irinotecan in an organoid- and CRISPR-Cas9-based murine model of gallbladder cancer. Cancers (Basel), 2019, 11(12): 1904. doi: 10.3390/cancers11121904.
18.	Scanu T, Spaapen RM, Bakker JM, et al. Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma. Cell Host Microbe, 2015, 17(6): 763-774.
19.	García P, Rosa L, Vargas S, et al. Hippo-YAP1 is a prognosis marker and potentially targetable pathway in advanced gallbladder cancer. Cancers (Basel), 2020, 12(4): 778. doi: 10.3390/cancers12040778.
20.	Angeles A, Hung W, Cheung WY. Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy. Med Oncol. 2018, 35(8): 114. doi:10.1007/s12032-018-1176-6.
21.	Saito Y, Muramatsu T, Kanai Y, et al. Establishment of patient-derived organoids and drug screening for biliary tract carcinoma. Cell Rep, 2019, 27(4): 1265-1276.
22.	Löffler MW, Chandran PA, Laske K, et al. Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient. J Hepatol, 2016, 65(4): 849-855.
23.	Neal JT, Li X, Zhu J, et al. Organoid modeling of the tumor immune microenvironment. Cell, 2018, 175(7): 1972-1988.
24.	Sui M, Li Y, Wang H, et al. Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade. J Immunother Cancer, 2019, 7(1): 125. doi: 10.1186/s40425-019-0596-y.
25.	Sampaziotis F, Muraro D, Tysoe OC, et al. Cholangiocyte organoids can repair bile ducts after transplantation in the human liver. Science, 2021, 371(6531): 839-846.
26.	Langhans SA. Using 3D in vitro cell culture models in anti-cancer drug discovery. Expert Opin Drug Discov, 2021, 16(8): 841-850.
27.	Driehuis E, Kretzschmar K, Clevers H. Establishment of patient-derived cancer organoids for drug-screening applications. Nat Protoc, 2020, 15(10): 3380-3409.
28.	Schutgens F, Clevers H. Human organoids: tools for understanding biology and treating diseases. Annu Rev Pathol, 2020, 15: 211-234.
29.	Yang H, Wang Y, Wang P, et al. Tumor organoids for cancer research and personalized medicine. Cancer Biol Med, 2021, 19(3): 319-332.
30.	周永杰, 石毓君. 类器官研究进展及展望. 中国普外基础与临床杂志, 2022, 29(6): 716-718.
31.	Driehuis E, van Hoeck A, Moore K, et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proc Natl Acad Sci USA, 2019, 116(52): 26580-26590.
32.	Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 2018, 359(6378): 920-926.
33.	van de Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell, 2015, 161(4): 933-945.
34.	Devarasetty M, Forsythe SD, Shelkey E, et al. In vitro modeling of the tumor microenvironment in tumor organoids. Tissue Eng Regen Med, 2020, 17(6): 759-771.
35.	Fauzi MB, Rashidbenam Z, Bin Saim A, et al. Preliminary study of in vitro three-dimensional skin model using an ovine collagen type Ⅰ sponge seeded with co-culture skin cells: submerged versus air-liquid interface conditions. Polymers (Basel), 2020, 12(12): 2784. doi: 10.3390/polym12122784.
36.	Gonzalez-Exposito R, Semiannikova M, Griffiths B, et al. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. J Immunother Cancer, 2019, 7(1): 101. doi: 10.1186/s40425-019-0575-3.
37.	Wen YA, Xing X, Harris JW, et al. Adipocytes activate mitochondrial fatty acid oxidation and autophagy to promote tumor growth in colon cancer. Cell Death Dis, 2017, 8(2): e2593. doi: 10.1038/cddis.2017.21.
38.	Usui T, Sakurai M, Enjoji S, et al. Establishment of a novel model for anticancer drug resistance in three-dimensional primary culture of tumor microenvironment. Stem Cells Int, 2016, 2016: 7053872. doi: 10.1155/2016/7053872.
39.	Charelli LE, Ferreira JPD, Naveira-Cotta CP, et al. Engineering mechanobiology through organoids-on-chip: a strategy to boost therapeutics. J Tissue Eng Regen Med, 2021, 15(11): 883-899.

1. Tansey W, Li K, Zhang H, et al. Dose-response modeling in high-throughput cancer drug screenings: an end-to-end approach. Biostatistics, 2022, 23(2): 643-665.
2. Wang H, Brown PC, Chow ECY, et al. 3D cell culture models: drug pharmacokinetics, safety assessment, and regulatory consideration. Clin Transl Sci, 2021, 14(5): 1659-1680.
3. Di-Luoffo M, Pirenne S, Saandi T, et al. A mouse model of cholangiocarcinoma uncovers a role for tensin-4 in tumor progression. Hepatology, 2021, 74(3): 1445-1460.
4. Lancaster MA, Knoblich JA. Organogenesis in a dish: modeling development and disease using organoid technologies. Science, 2014, 345(6194): 1247125. doi: 10.1126/science.1247125.
5. Bruun J, Kryeziu K, Eide PW, et al. Patient-derived organoids from multiple colorectal cancer liver metastases reveal moderate intra-patient pharmacotranscriptomic heterogeneity. Clin Cancer Res, 2020, 26(15): 4107-4119.
6. Nanki Y, Chiyoda T, Hirasawa A, et al. Patient-derived ovarian cancer organoids capture the genomic profiles of primary tumours applicable for drug sensitivity and resistance testing. Sci Rep, 2020, 10(1): 12581. doi: 10.1038/s41598-020-69488-9.
7. 尹健一, 李幼生, 黎介寿. 小肠类器官的构建与应用进展. 中华实验外科杂志, 2019, 36(7): 1344-1347.
8. 范圣先, 尹健一, 王剑, 等. 胃干细胞调控机制及其在胃类器官构建中的应用研究. 中华消化外科杂志, 2019, 18(3): 287-291.
9. 李向阳, 赵鑫, 相小松, 等. 诱导型多能干细胞在体外三维环境中诱导分化出肠道类器官. 中国组织工程研究, 2017, 21(25): 4057-4061.
10. 耿艳霞, 黎介寿, 李秋荣. 肠道干细胞与肠道损伤修复的研究进展. 医学研究生学报, 2013, 26(2): 181-185.
11. Huang Z, Ruan HB, Zhang ZD, et al. Mutation in the first Ig-like domain of Kit leads to JAK2 activation and myeloproliferation in mice. Am J Pathol, 2014, 184(1): 122-132.
12. Yuan B, Zhao X, Wang X, et al. Patient-derived organoids for personalized gallbladder cancer modelling and drug screening. Clin Transl Med, 2022, 12(1): e678. doi: 10.1002/ctm2.678.
13. Wang Z, Guo Y, Jin Y, et al. Establishment and drug screening of patient-derived extrahepatic biliary tract carcinoma organoids. Cancer Cell Int, 2021, 21(1): 519. doi: 10.1186/s12935-021-02219-w.
14. 袁波. 胆囊良恶性肿瘤类器官培养体系的建立及鉴定. 上海: 中国人民解放军海军军医大学, 2019.
15. Kasuga A, Semba T, Sato R, et al. Oncogenic KRAS-expressing organoids with biliary epithelial stem cell properties give rise to biliary tract cancer in mice. Cancer Sci, 2021, 112(5): 1822-1838.
16. Pérez-Moreno P, Riquelme I, García P, et al. Environmental and lifestyle risk factors in the carcinogenesis of gallbladder cancer. J Pers Med, 2022, 12(2): 234. doi: 10.3390/jpm12020234.
17. Erlangga Z, Wolff K, Poth T, et al. Potent antitumor activity of liposomal irinotecan in an organoid- and CRISPR-Cas9-based murine model of gallbladder cancer. Cancers (Basel), 2019, 11(12): 1904. doi: 10.3390/cancers11121904.
18. Scanu T, Spaapen RM, Bakker JM, et al. Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma. Cell Host Microbe, 2015, 17(6): 763-774.
19. García P, Rosa L, Vargas S, et al. Hippo-YAP1 is a prognosis marker and potentially targetable pathway in advanced gallbladder cancer. Cancers (Basel), 2020, 12(4): 778. doi: 10.3390/cancers12040778.
20. Angeles A, Hung W, Cheung WY. Eligibility of real-world patients with chemo-refractory, K-RAS wild-type, metastatic colorectal cancer for palliative intent regorafenib monotherapy. Med Oncol. 2018, 35(8): 114. doi:10.1007/s12032-018-1176-6.
21. Saito Y, Muramatsu T, Kanai Y, et al. Establishment of patient-derived organoids and drug screening for biliary tract carcinoma. Cell Rep, 2019, 27(4): 1265-1276.
22. Löffler MW, Chandran PA, Laske K, et al. Personalized peptide vaccine-induced immune response associated with long-term survival of a metastatic cholangiocarcinoma patient. J Hepatol, 2016, 65(4): 849-855.
23. Neal JT, Li X, Zhu J, et al. Organoid modeling of the tumor immune microenvironment. Cell, 2018, 175(7): 1972-1988.
24. Sui M, Li Y, Wang H, et al. Two cases of intrahepatic cholangiocellular carcinoma with high insertion-deletion ratios that achieved a complete response following chemotherapy combined with PD-1 blockade. J Immunother Cancer, 2019, 7(1): 125. doi: 10.1186/s40425-019-0596-y.
25. Sampaziotis F, Muraro D, Tysoe OC, et al. Cholangiocyte organoids can repair bile ducts after transplantation in the human liver. Science, 2021, 371(6531): 839-846.
26. Langhans SA. Using 3D in vitro cell culture models in anti-cancer drug discovery. Expert Opin Drug Discov, 2021, 16(8): 841-850.
27. Driehuis E, Kretzschmar K, Clevers H. Establishment of patient-derived cancer organoids for drug-screening applications. Nat Protoc, 2020, 15(10): 3380-3409.
28. Schutgens F, Clevers H. Human organoids: tools for understanding biology and treating diseases. Annu Rev Pathol, 2020, 15: 211-234.
29. Yang H, Wang Y, Wang P, et al. Tumor organoids for cancer research and personalized medicine. Cancer Biol Med, 2021, 19(3): 319-332.
30. 周永杰, 石毓君. 类器官研究进展及展望. 中国普外基础与临床杂志, 2022, 29(6): 716-718.
31. Driehuis E, van Hoeck A, Moore K, et al. Pancreatic cancer organoids recapitulate disease and allow personalized drug screening. Proc Natl Acad Sci USA, 2019, 116(52): 26580-26590.
32. Vlachogiannis G, Hedayat S, Vatsiou A, et al. Patient-derived organoids model treatment response of metastatic gastrointestinal cancers. Science, 2018, 359(6378): 920-926.
33. van de Wetering M, Francies HE, Francis JM, et al. Prospective derivation of a living organoid biobank of colorectal cancer patients. Cell, 2015, 161(4): 933-945.
34. Devarasetty M, Forsythe SD, Shelkey E, et al. In vitro modeling of the tumor microenvironment in tumor organoids. Tissue Eng Regen Med, 2020, 17(6): 759-771.
35. Fauzi MB, Rashidbenam Z, Bin Saim A, et al. Preliminary study of in vitro three-dimensional skin model using an ovine collagen type Ⅰ sponge seeded with co-culture skin cells: submerged versus air-liquid interface conditions. Polymers (Basel), 2020, 12(12): 2784. doi: 10.3390/polym12122784.
36. Gonzalez-Exposito R, Semiannikova M, Griffiths B, et al. CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids. J Immunother Cancer, 2019, 7(1): 101. doi: 10.1186/s40425-019-0575-3.
37. Wen YA, Xing X, Harris JW, et al. Adipocytes activate mitochondrial fatty acid oxidation and autophagy to promote tumor growth in colon cancer. Cell Death Dis, 2017, 8(2): e2593. doi: 10.1038/cddis.2017.21.
38. Usui T, Sakurai M, Enjoji S, et al. Establishment of a novel model for anticancer drug resistance in three-dimensional primary culture of tumor microenvironment. Stem Cells Int, 2016, 2016: 7053872. doi: 10.1155/2016/7053872.
39. Charelli LE, Ferreira JPD, Naveira-Cotta CP, et al. Engineering mechanobiology through organoids-on-chip: a strategy to boost therapeutics. J Tissue Eng Regen Med, 2021, 15(11): 883-899.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Advances in research of gallbladder cancer organoid

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content